Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Diabetic Microvascular Dysfunction and Metabolic Stress: Full Study

Previous related pageVitamin D, Diabetic Microvascular Dysfunction and Metabolic Stress: Study SummaryNext related pageVitamin D, Diabetic Microvascular Dysfunction and Metabolic Stress: Study Summary
Study at a glance

How was vitamin D studied in diabetes and small blood vessels?

One study compared two vitamin D3 doses in people with type 2 diabetes and peripheral neuropathy, meaning damage to nerves outside the brain and spinal cord. A separate study tested active vitamin D in blood-vessel lining cells grown in the laboratory that were exposed to high glucose. They examined different parts of a possible link between vitamin D, inflammation and small-vessel function.

What did the vitamin D3 study in people with diabetes report?

Sixty-seven people entered the 24-week study, and 62 completed it. The higher-dose group had reported improvements in selected skin blood-flow tests, some measured signs of inflammation and nerve-symptom scores. Weight and glucose control also changed. Both groups received vitamin D, treatment was known, and people were assigned to groups using a predictable even/odd method. Reporting inconsistencies further limit confidence. The study therefore could not securely show that vitamin D directly caused the vessel changes or repaired nerves.

What did active vitamin D change in cells exposed to high glucose?

Active vitamin D reduced several injury-related signals in cells exposed to high glucose. Making the cells produce more of a protein called TIPE1 opposed some of these effects, suggesting a role for that protein. This did not establish the complete mechanism or a treatment for people. The experiments had limited repetition and lacked a control needed to separate glucose-specific effects from other effects of the solution.

Do these findings establish nerve repair or prevention of diabetic complications?

A separate comparison found lower vitamin D and higher TIPE1-related measurements in people with diabetic complications, but other differences could explain the link. Neither study directly measured improved oxygen delivery to nerves or demonstrated prevention of ulcers, kidney disease or eye complications. The human study did not test TIPE1, and the cell study did not measure blood flow in an intact vessel. These findings do not establish an ideal dose or general treatment safety.

Read the full article below ↓

Does vitamin D alter small-vessel dysfunction in the metabolic environment of diabetes, and which signalling pathways might connect the two? A human supplementation study reported changes in skin microcirculation and selected inflammatory markers. A separate cell study investigated injury under high glucose and a protein called TIPE1. Their findings are suggestive, but neither establishes a complete causal pathway from supplementation to prevention of diabetic complications. For the shorter account, read Vitamin D, Diabetic Microvascular Dysfunction and Metabolic Stress: Study Summary.

Why the diabetic setting changes the question

Diabetes can expose small vessels to prolonged metabolic and inflammatory stress. This makes the question more specific than whether vitamin D affects circulation in healthy volunteers. The microcirculation overview provides the anatomical context, while the studies examined here ask about functional skin responses and endothelial-cell injury. They did not directly measure whether capillaries supplied more oxygen to nerves, kidneys or the retina.

Several processes may change together: blood glucose, body weight, circulating inflammatory messengers and local vascular responses. The relationship with metabolic flexibility concerns how tissues handle changing fuel demands, but neither paper directly tested switching between glucose and fat as fuels. Metabolic improvement cannot simply be assumed to explain a vascular change without an analysis or experiment that tests that connection.

Karonova: two oral doses in people with diabetic neuropathy

Karonova and colleagues screened 98 people and enrolled 67 with type 2 diabetes and peripheral neuropathy. Eligible participants were 18 to 65 years old, had diabetes for at least five years, had glycated haemoglobin below 9%, and were on stable glucose-lowering and other relevant treatment. Glycated haemoglobin, commonly called HbA1c, reflects blood glucose exposure over preceding months. The study excluded smokers, diabetic foot disease, certain vascular and inflammatory conditions, vitamin B12 deficiency and several medicines used for pain.

The investigators allocated 34 participants to 5,000 international units of cholecalciferol, or vitamin D3, weekly and 33 to 40,000 units weekly for 24 weeks. Although described as randomised, allocation used an even/odd method. Such a predictable sequence does not provide the same protection against selection bias as concealed random allocation. Treatment was open label, and both groups received active vitamin D. The comparison therefore concerns two dosing strategies rather than supplementation against placebo.

Five people withdrew shortly after allocation: three declined further participation and two developed an upper respiratory infection. The analysed sample comprised 31 completers per group. Their median age was 56 years, and most had low vitamin D status by the paper’s definitions. The report does not provide a full intention-to-treat analysis preserving everyone originally allocated. Its public registration was first posted in May 2020, after the recorded study completion, so it cannot establish prospective outcome registration. The registry also lists 68 enrolled participants, whereas the article and flowchart report 67.

What the clinical measurements actually show

Skin microcirculation was assessed on the underside of the big toe using laser-Doppler flowmetry. After rest in a temperature-controlled room, the researchers measured basal perfusion and responses to temporary occlusion and a postural challenge. These tests describe aspects of local blood-flow regulation. They do not visualise every capillary or measure oxygen extraction by a nerve. The postural response includes a reduction in local flow, illustrating why a larger number does not always mean more blood should flow under every condition.

The higher-dose group showed reported improvements in several flow indices. Its tabulated basal perfusion value rose from 6.01 to 7.01 perfusion units, while the coefficient describing flow variability rose from 16.65% to 27.96%. The reported capillary-reserve index rose from 48.57% to 106.8%. These are instrument: and protocol-specific quantities. They must not be relabelled percentage increases in total-body circulation, capillary growth or nerve oxygen delivery.

Important reporting inconsistencies limit numerical certainty. Table 3 presents values with a plus-or-minus format but labels them medians and interquartile ranges. The prose says maximal post-occlusion flow increased in both groups, while the lower-dose values in the table fall from 9.73 to 8.97. The reserve-index definition is also insufficiently clear for reconstructing the reported percentages from aggregate values. These discrepancies are not silently corrected here. They weaken confidence in a precise effect estimate even though the higher-dose group’s reported directions are broadly favourable.

The authors used within-group Wilcoxon tests and between-group Mann: Whitney tests, with nominal significance at P < 0.05. Several outcomes and correlations were examined without a reported comprehensive multiplicity adjustment. A significant change in one group and a nonsignificant change in another is not itself proof that their changes differ. The report lacks the clarity of a prespecified, confidence-interval-based comparison of changes, so its results are best treated as exploratory evidence needing replication.

Inflammatory and metabolic changes occurred together

In the higher-dose group, median serum 25-hydroxyvitamin D rose from 16.2 to 71.6 ng/mL; in the lower-dose group it rose from 18.8 to 26.9 ng/mL. These are achieved study concentrations, not recommended targets. The higher-dose group’s median interleukin-6 fell from 2.5 to 0.6 pg/mL and interleukin-10 rose from 2.5 to 4.5 pg/mL. These are immune signalling proteins. Other measured markers, including C-reactive protein, tumour necrosis factor alpha and interleukin-1 beta, did not show significant changes.

The inflammatory result was therefore selective, not a demonstrated improvement in every aspect of inflammation. Body weight and glucose control also changed: 19 of 31 higher-dose participants lost more than 5% of body weight, and median HbA1c fell from 7.9% to 7.4%. The researchers reported stable background medicines, but the design does not establish whether vitamin D acted directly on vessels, whether changes in weight or glucose contributed, or whether other behaviour affected several outcomes together. Correlations cannot settle those alternatives.

Neuropathy scores improved in the higher-dose group, but those findings need proportionate interpretation. The median disability score fell from eight to six, while median pain on a 100-mm visual scale fell from 50 to 47 mm. A small P value does not make that three-millimetre difference a large or established clinically meaningful benefit. No nerve-conduction study, nerve-fibre biopsy or direct intraneural perfusion measurement demonstrated repair. Nor did the trial establish prevention of ulcers, kidney disease or retinal complications.

Liu: testing an endothelial response to high glucose

Liu and colleagues used cultured human umbilical vein endothelial cells at passages three to six. The cells were exposed to 35 millimolar glucose for 12 hours, followed by 100 nanomolar calcitriol for the principal 24-hour treatment protocol. Calcitriol is the active vitamin D hormone, distinct from the oral cholecalciferol used in the clinical study. The normal-glucose comparator contained 5.6 millimolar glucose. Assays also included later observation times.

The experiments examined cell viability, movement through a membrane, programmed cell death, oxidant-related fluorescence and cellular recycling structures. High glucose worsened several measures; calcitriol reduced injury signals and improved migration and viability. For example, Figure 2 shows roughly 40% positive cell-death staining with high glucose at the 24-hour assessment versus roughly 20% with calcitriol. These are approximate visual descriptions of the graph, not newly digitised estimates or percentages of rescued human vessels.

The candidate protein was tumour necrosis factor alpha-induced protein 8-like 1, abbreviated TIPE1. Its abundance rose under high glucose and fell with calcitriol. Forcing cells to produce more TIPE1 counteracted several calcitriol-associated responses, including lower oxidant signals, better migration and lower cell-death measures. This experimental perturbation supports a role for TIPE1 in that culture system. It does not show that TIPE1 is the sole mediator or that reducing it would safely treat a person with diabetes.

The link with vitamin D receptors remains partly proposed. A computer analysis identified possible receptor-binding sites in the TIPE1 gene’s promoter, the region involved in controlling gene activity. Predicted sites are not evidence of receptor occupancy in living endothelial cells. The paper did not establish the proposed promoter mechanism with receptor-binding or promoter-mutation experiments. Its pathway diagram is a hypothesis informed by the experiments and other literature, not a fully tested chain.

The study reported three independent experimental replicates and means with standard deviations. That provides limited replication, not a broad sample of adult human microvascular tissues. Umbilical-vein cells are a large-vessel model. The reported design also lacks a matched osmotic control to separate glucose-specific injury from effects of the increased solute concentration. Changes in colour-producing viability assays and fluorescence should be read as assay responses, with their own specificity limits.

Where cellular signalling and human disease remain separate

Liu’s clinical component compared 40 people with diabetes and complications with 40 without complications. Vitamin D measurements were lower and TIPE1 messenger RNA measurements higher in the complication group. Body mass index and waist circumference also differed. This was an observational comparison, with limited detail about the vitamin D analyte and no adequate adjusted causal model. It does not establish that low vitamin D caused the complications or that blood TIPE1 reflects the endothelial mechanism measured in culture.

The discussion additionally mentions improved diabetes biomarkers with insulin plus vitamin D, but the paper supplies no corresponding clinical intervention methods and results. That statement is not treated here as evidence of treatment efficacy. The supported experimental finding is narrower: active-hormone exposure changed selected high-glucose cell responses, and artificial TIPE1 overexpression opposed several of those changes. No clinical benefit should be inferred from an unexplained discussion statement.

The connection with endothelial function is biologically plausible because the cell model represents part of the vessel lining. Measurements related to endothelin and nitric oxide also touch on vascular tone, the regulation of vessel contraction and relaxation. However, the cell study did not measure an intact vessel’s diameter or flow, and the clinical trial did not measure TIPE1. The studies therefore do not directly verify each other’s mechanism.

Distinguishing vitamin D status from vitamin D effect prevents conflating blood concentrations, active-hormone exposure and tissue responses. Applying the evidence hierarchy to these two papers yields a bounded conclusion: selected clinical and cellular signals justify further controlled investigation, while reporting inconsistencies, confounding and model differences prevent a secure claim of microvascular protection. Neither study establishes an optimal dose, general treatment safety or prevention of diabetic complications.

Scientific sources

Karonova T, Stepanova A, Bystrova A, Jude EB. High-Dose Vitamin D Supplementation Improves Microcirculation and Reduces Inflammation in Diabetic Neuropathy Patients. Nutrients. 2020;12:2518. DOI: 10.3390/nu12092518. PMID: 32825324. The complete principal paper, participant flow diagram and three tables were examined.

Liu Z, Sun H, Chen Y, He J, Zhu L, Yang B, Zhao W. High glucose-induced injury in human umbilical vein endothelial cells is alleviated by vitamin D supplementation through downregulation of TIPE1. Diabetology & Metabolic Syndrome. 2024;16:18. DOI: 10.1186/s13098-024-01264-5. PMID: 38216955. The complete principal paper, all six figures and clinical table were examined.

ClinicalTrials.gov. High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy. NCT04377399. First posted 6 May 2020, after the recorded study completion. This is the registration for the Karonova trial, not an independent efficacy study.

Related reading

Original sources

Source

High-Dose Vitamin D Supplementation Improves Microcirculation and Reduces Inflammation in Diabetic Neuropathy Patients

Published in Nutrients (2020).

Publication details

Karonova T, Stepanova A, Bystrova A, Jude EB. High-Dose Vitamin D Supplementation Improves Microcirculation and Reduces Inflammation in Diabetic Neuropathy Patients. Nutrients. 2020;12:2518. DOI: 10.3390/nu12092518. PMID: 32825324. The complete principal paper, participant flow diagram and three tables were examined.

Read more →
Source

High glucose-induced injury in human umbilical vein endothelial cells is alleviated by vitamin D supplementation through downregulation of TIPE1

Published in Diabetology & Metabolic Syndrome (2024).

Publication details

Liu Z, Sun H, Chen Y, He J, Zhu L, Yang B, Zhao W. High glucose-induced injury in human umbilical vein endothelial cells is alleviated by vitamin D supplementation through downregulation of TIPE1. Diabetology & Metabolic Syndrome. 2024;16:18. DOI: 10.1186/s13098-024-01264-5. PMID: 38216955. The complete principal paper, all six figures and clinical table were examined.

Read more →
Trial registry

High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy

ClinicalTrials.gov. High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy.

Publication details

ClinicalTrials.gov. High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy. NCT04377399. First posted 6 May 2020, after the recorded study completion. This is the registration for the Karonova trial, not an independent efficacy study.

Read more →